All In MedTech

Device Trial Radar · NCT01650948

Genetic Load and Phenotype in Aggressive AMD

Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.

Last checked: Nov 19, 2026Latest source record: Jan 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Jul 2012

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
Sequenom, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2012

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).

Conditions

  • Age-related Macular Degeneration

Interventions

  • RetnaGene AMD LDTDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The identification of individual genetic markers or a quantitative measure of total genetic burden found to be significantly associated (p value <0.05) with group classification (CNV only versus CNV with GA and/or RPED).Time frame: 1 day

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Pacific Eye Associates

    San Francisco, California

  • Retina Associates of Kentucky

    Lexington, Kentucky

  • Tennessee Retina

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.